Accent Microcell gears up for IPO targeting India’s pharma sector By Investing.com
[ad_1]
© Reuters.
MUMBAI – Accent Microcell, known for its high-quality pharmaceutical excipients, is preparing to launch its initial public offering (IPO) between December 8-12. The company is eyeing India’s rapidly growing pharmaceutical market, which is projected to reach $130 billion by 2030. The IPO aims to raise ₹78 crore through the offering of up to 56 lakh shares priced between ₹133 and ₹140 each.
With first-quarter revenues reported at ₹59.9 crore (INR10 crore = approx. USD1.2 million) and profits at ₹7.05 crore, Accent Microcell’s IPO proceeds are earmarked for significant expansion plans. The funds will be utilized to establish new manufacturing facilities for key products such as Croscarmellose Sodium and Sodium Starch Glycolate, in addition to enhancing production capabilities for microcrystalline cellulose (CMC), a widely used excipient in the pharmaceutical and cosmetics industries.
Corporate Capital Ventures is managing the IPO process, with Kfin Technologies appointed as the registrar. The company has outlined investor categories in preparation for its listing on the NSE SME platform. The final allotment of shares is scheduled for today, with the listing expected to take place on December 15.
This strategic move comes as Accent Microcell positions itself to capitalize on the increasing demand within India’s burgeoning pharma sector. By expanding its production capacity and product range, the company is set to play a pivotal role in meeting the industry’s needs for high-quality excipients derived from wood pulp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
MUMBAI – Accent Microcell, known for its high-quality pharmaceutical excipients, is preparing to launch its initial public offering (IPO) between December 8-12. The company is eyeing India’s rapidly growing pharmaceutical market, which is projected to reach $130 billion by 2030. The IPO aims to raise ₹78 crore through the offering of up to 56 lakh shares priced between ₹133 and ₹140 each.
With first-quarter revenues reported at ₹59.9 crore (INR10 crore = approx. USD1.2 million) and profits at ₹7.05 crore, Accent Microcell’s IPO proceeds are earmarked for significant expansion plans. The funds will be utilized to establish new manufacturing facilities for key products such as Croscarmellose Sodium and Sodium Starch Glycolate, in addition to enhancing production capabilities for microcrystalline cellulose (CMC), a widely used excipient in the pharmaceutical and cosmetics industries.
Corporate Capital Ventures is managing the IPO process, with Kfin Technologies appointed as the registrar. The company has outlined investor categories in preparation for its listing on the NSE SME platform. The final allotment of shares is scheduled for today, with the listing expected to take place on December 15.
This strategic move comes as Accent Microcell positions itself to capitalize on the increasing demand within India’s burgeoning pharma sector. By expanding its production capacity and product range, the company is set to play a pivotal role in meeting the industry’s needs for high-quality excipients derived from wood pulp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
